Subtotal colectomy with Deloyers colo-anal anastomosis for refractory ulcerative colitis: A case report

Table 1 Summary of clinical, biochemical, and endoscopic parameters over time

Parameter	At referral	After infliximab	After 4 months of standard dose tofacitinib	After 4 months of high-dose tofacitinib	6 months post-surgery
Clinical symptoms	Bloody diarrhea (6-7/day)	Not improved	Improved	Clinical remission	Asymptomatic
Hemoglobin (g/L)	83	83	109	125	138
Albumin (g/L)	29.8	31.3	30	36.0	45.0
CRP (mg/L)	50.4	70.0	38	9.5	1.9
Fecal calprotectin (μg/g)	> 800	> 800	> 800	317	Not assessed
MES	3 (pancolitis)	3 (pancolitis)	3 (distal)/2 (proximal)	3 (distal)/0-1 (proximal)1	No active UC
Full Mayo Score	12	12	9	61	0-1

¹The Full Mayo Score of 6 despite clinical remission reflects this discordance, driven by the severe distal Mayo Endoscopic Score while stool frequency and rectal bleeding subscores had normalized.

This table illustrates the patient’s clinical-endoscopic discordance: Significant improvement in symptoms and biochemical markers during high-dose tofacitinib contrasted with persistently severe distal inflammation (Mayo Endoscopic Score 3), ultimately necessitating surgery. CRP: C-reactive protein; MES: Mayo Endoscopic Score.